Polomar Pulls Two Quarterly Reports, Expects ~$421K Additional Net Loss and Material Weaknesses
PMHS has more than doubled off its 52-week low of $0.065.
Summary
Polomar's Audit Committee concluded the Q1 and Q2 2026 financials can no longer be relied upon, with corrections expected to add about $421,000 to net losses and material weaknesses anticipated.
Key Events · Legal and Risk Events · PMHS
-
Two Quarters No Longer Reliable
On November 1, 2026, the Audit Committee concluded that the 10-Q for the three months ended March 31, 2026 (filed June 1, 2026) and the 10-Q for the three and six months ended June 30, 2026 (filed August 14, 2026) should no longer be relied upon.
-
~$421K Hit to Net Loss
Corrections are estimated to increase net loss by approximately $421,000 in aggregate — about $332,000 for Q1 2026 and $89,000 for Q2 2026 — from lower revenue and higher cost of goods sold, operating expenses and interest expense. The estimate is preliminary and excludes the preferred-stock reclassification.
-
Material Weaknesses Expected
Management is reassessing disclosure controls and internal control over financial reporting and expects to report one or more material weaknesses.
-
10-Q/A Restatements Pending
The company intends to restate the affected quarters in Form 10-Q/A amendments it expects to file as soon as practicable; the final adjustments may differ from the preliminary estimate.
Analysis · PMHS · Life Sciences
Investors have been told to stop relying on both the Q1 and Q2 2026 financial statements after the Audit Committee found errors across revenue, inventory, commission and interest expense, plus a preferred-stock misclassification. The correction is expected to add roughly $421,000 to net losses, and management expects to report one or more material weaknesses in internal control. For a company already flagged with going-concern doubt and material weakness in its last 10-Q, a restatement of two quarters removes the credibility of the reported numbers investors were using to value the business, and the 10-Q/A filings are still pending.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 50.3% of the 199 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMHS was trading at $0.19 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.07 to $840,000.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.